DEprescribing: Perceptions of PAtients Living With Advanced Cancer
Launched by NANTES UNIVERSITY HOSPITAL · Jan 4, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "DEprescribing: Perceptions of Patients Living With Advanced Cancer," is focused on understanding how patients with advanced cancer feel about reducing the number of medications they take. Many patients in palliative care—those receiving treatment aimed at relieving symptoms rather than curing the illness—often find themselves on multiple medications, which can lead to more health problems and a lower quality of life. The goal of this study is to learn more about patients' views on deprescribing, which means safely stopping unnecessary medications, and to identify factors that influence these views. The researchers will also assess how well patients understand health information and how that affects their feelings about their medications.
To participate in this study, individuals must be over 18 years old, have advanced or metastatic solid cancer, and their doctor must estimate that they have less than one year to live. Participants will complete interviews and questionnaires to share their experiences and beliefs about medication use. The insights gained from this trial aim to improve how healthcare providers approach medication management for patients in palliative care, ultimately helping to enhance their quality of life and reduce the risks associated with taking too many medications.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient over 18 years of age
- • Locally advanced or metastatic solid cancer (i.e., palliative care as defined by the World Health Organization)
- • Life expectancy estimated by the physician at inclusion of less than 1 year (use of surprise question to help clinician estimate life expectancy)
- • Hospitalized or in consultation
- • With at least one PIMs (identified using STOPPfrail 2)
- • Patient not having expressed opposition to participating in the study after receiving information from the physician.
- For qualitative study patients :
- • - Patients who have signed an authorization for the recording of their voice during the semi-structured interview for the purpose of written transcription.
- Exclusion Criteria:
- • Minor
- • Major under guardianship, protected person
- • Patient unable to speak or write French
- • Patient with impaired judgment, cognitive or sensory impairment that prevents him/her from receiving informed information, answering questionnaires or participating in a study interview.
About Nantes University Hospital
Nantes University Hospital, a leading academic medical institution in France, is dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge scientific exploration with patient care, fostering collaborations among multidisciplinary teams of healthcare professionals and researchers. With a strong emphasis on ethical standards and patient safety, Nantes University Hospital aims to contribute to the development of effective therapies and interventions that enhance patient outcomes and overall public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nantes, , France
Tours, , France
La Roche Sur Yon, , France
Saint Herblain, , France
Saint Nazaire, , France
Paris, , France
Patients applied
Trial Officials
Adrien EVIN
Principal Investigator
Nantes University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported